Floatz logo

57 assets in Ewing Sarcoma

Therapeutic assets addressing Ewing Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Irinotecan
Ewing Sarcoma
Milton S. Hershey Medical CenterP3BB (66)
Nivolumab
Ewing Sarcoma
Children's National Research InstituteP2B (62)
Cyclophosphamide
Ewing Sarcoma
Essen BiotechP2B (61)
Adriamycin
Ewing Sarcoma
Children's National Research InstituteP2B (58)
Nogitecan
Ewing Sarcoma
PfizerP2B (58)
Ipilimumab
Ewing Sarcoma
Children's National Research InstituteP2B (57)
Palbociclib
Ewing Sarcoma
Dana-Farber Cancer InstituteP2B (57)
PI3K/MTOR INHIBITOR LY3023414
Ewing Sarcoma
National Cancer Institute (NCI)P2B (57)
Tazemetostat
Ewing Sarcoma
National Cancer Institute (NCI)P2B (57)
Fludarabine
Ewing Sarcoma
Essen BiotechP1/2CCC (55)
Vemurafenib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Ivosidenib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
L-Methionine
Ewing Sarcoma
St. Jude Children's Research HospitalP2CCC (53)
Olaparib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Selpercatinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Selumetinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Ewing Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Talazoparib
Ewing Sarcoma
St. Jude Children's Research HospitalP1/2CCC (52)
Carboplatin
Ewing Sarcoma
Inhibrx Biosciences, IncP1/2CCC (50)
Mesna
Ewing Sarcoma
St. Jude Children's Research HospitalP1/2CCC (50)
(+)-Vincristine
Ewing Sarcoma
National Cancer Institute (NCI)P1/2CCC (50)
Zoledronate
Ewing Sarcoma
University of FloridaP1/2CCC (50)
cd146/her2 car-t cells
Ewing Sarcoma
Essen BiotechP1/2CCC (48)
Elimusertib
Ewing Sarcoma
National Cancer Institute (NCI)P1/2CCC (48)
Locnartecan
Ewing Sarcoma
National Cancer Institute (NCI)P1/2CCC (48)
Lurbinectedin
Ewing Sarcoma
Jazz PharmaceuticalsP1/2CCC (48)
Onivyde
Ewing Sarcoma
St. Jude Children's Research HospitalP1/2CCC (48)
Surufatinib
Ewing Sarcoma
HutchmedP1/2CCC (48)
Tegavivint
Ewing Sarcoma
Children's Oncology GroupP1/2CCC (48)
gd2-cart01
Ewing Sarcoma
Bambino Gesù Hospital and Research InstituteP1/2CC (45)
Sarcoma-Specific Car-T Cells
Ewing Sarcoma
Shenzhen Geno-Immune Medical InstituteP1/2CC (45)
Silmitasertib
Ewing Sarcoma
Milton S. Hershey Medical CenterP1/2CC (45)
Zilovertamab Vedotin
Ewing Sarcoma
Merck Sharp & Dohme LLCP1/2CC (45)
c7r-gd2.cart cells
Ewing Sarcoma
Baylor College of MedicineP1CC (43)
[111in]-fpi-2058
Ewing Sarcoma
3B Pharmaceuticals GmbHP1CC (41)
[225]-fpi-2059
Ewing Sarcoma
3B Pharmaceuticals GmbHP1CC (41)
b7-h3 car t cells
Ewing Sarcoma
St. Jude Children's Research HospitalP1CC (41)
dxc008
Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.P1CC (41)
Fluorouracilum
Ewing Sarcoma
Inhibrx Biosciences, IncP1CC (41)
Iopofosine (¹³¹I)
Ewing Sarcoma
Cellectar Biosciences, Inc.P1CC (41)
Lifileucel
Ewing Sarcoma
Iovance Biotherapeutics, Inc.P1CC (41)
ln-144
Ewing Sarcoma
Iovance Biotherapeutics, Inc.P1CC (41)
Ozekibart
Ewing Sarcoma
Inhibrx Biosciences, IncP1CC (41)
Pembrolizumab
Ewing Sarcoma
Seattle Children's HospitalP1CC (41)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr
Ewing Sarcoma
Seattle Children's HospitalP1CC (41)
Showing 1 to 50 of 57 assets
PreviousPage 1 of 2Next